US Bio association expresses negative response on biosimilars

The US Senate introduced a bipartisan bill on March 26, 2009, which establishes a regulatory pathway for approval of biosimilars.

A key provision in the Senate bill is to establish five years of market exclusivity for a biologic product from the time the brand-name drug was approved. The bill also establishes a procedure for resolution of patent disputes before a biosimilar is approved and e...